-
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
13 May 2024 20:10 GMT
… stage pharmaceutical company that aims to discover and develop … -in-human, clinical trial of ORX750, a … the European Association for Haemophilia and Allied Disorders ( … Drug Administration (FDA) has granted Fast Track designation to SerpinPC for the treatment …
-
Emicizumab brings hope to Haemophilia A patients, accessibility remains a challenge
07 May 2024 08:54 GMT
… largest and broadest trial programme spanning over … informed that the drug for haemophilia A treatment comes with a … experts, joint efforts by pharmaceutical companies, healthcare providers, … novel drugs or any medical interventions in the developing world …
-
NICE recommends new haemolytic anaemia treatment
03 May 2024 18:17 GMT
… Innovative Medicines Fund, which enables treatment to be offered without delay … Stephenson shared.
Another recent regulatory development for Pfizer was the regulatory … Food and Drug Administration (FDA) for a gene therapy to treat haemophilia B.
EMA …
-
Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A
03 May 2024 07:23 GMT
… weekly treatment for haemophilia A.
The treatment has been recommended to help treat and … Food and Drug Administration after the regulator previously grantedthe treatment breakthrough … drug designation in 2017.
Sanofi and Sobi collaborate on the development …
-
Weight-loss Drug Maker Novo Nordisk's Profits Soar Further
02 May 2024 09:37 GMT
… Joergensen
AFP
Danish pharmaceutical giant Novo Nordisk … regulators to treat obesity.
The treatments use analogues … blockbuster drugs, Novo Nordisk is acquiring US drug manufacturing … also develops treatments for rare diseases such as haemophilia and …
-
FDA approves Labcorp companion diagnostic for Pfizer gene therapy
30 Apr 2024 19:57 GMT
… FDA-approved haemophilia B gene therapy. Beqvez was approved to treat … market for haemophilia A and haemophilia B treatments will grow … diagnostic for BioMarin Pharmaceutical’s haemophilia A gene therapy … a collaboration to develop next-generation sequencing- …
-
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
30 Apr 2024 13:01 GMT
… new drug to be indicated for the treatment of … Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to development … reactions including food, medications and insect bites … , including those that treat haemophilia and immune deficiencies, …
-
Labcorp gets US FDA approval for first companion diagnostic for use with Pfizer's newly approved gene therapy to treat patients with haemophilia B
30 Apr 2024 10:14 GMT
… treatment with Beqvez (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved haemophilia … that treats eligible patients with haemophilia B … biomarker and CDx development, and post- … doctors, hospitals, pharmaceutical companies, researchers …
-
Is pharma’s interest in orphan drugs waning?
29 Apr 2024 09:46 GMT
… -defined populations and development incentives continue to … FDA’s new drug approvals in 2023 were for orphan drugs … Hemlibra (emicizumab) for haemophilia A treatment, retaining their current … and cancer drugs paltusotine from Crinetics Pharma and bemarituzumab …
-
Pfizer offers warranty for new haemophilia B therapy Beqvez
29 Apr 2024 09:46 GMT
… rival treatment.
Beqvez (fidanacogene elaparvovec) was approved by the FDA on … quarter.
It is the pharma giant’s first gene therapy … phase 1/2 trial, showing they had no … meanwhile, is also developing gene therapies for haemophilia A and Duchenne muscular …